Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension.
Sixteen patients with severe hypertension were treated for 1 year with extended release nifedipine, during which time serial changes in left ventricular mass index and associated alterations in left ventricular systolic function, left ventricular filling, plasma renin activity, atrial natriuretic peptide and catecholamines were evaluated. Mean seated blood pressure (+/- SE) was significantly reduced from 200 +/- 8/122 +/- 3 to 144 +/- 5/89 +/- 2 mm Hg (p less than 0.0001) at 1 year. After 6 months, left ventricular mass index was significantly reduced by 19% from 121 +/- 8 to 96 +/- 7 g/m2 and this reduction was sustained at 1 year. Septal and posterior wall thickness were reduced from 13.4 +/- 0.1 to 11.2 +/- 0.04 mm and from 12.8 +/- 0.1 to 10.0 +/- 0.03 mm (p less than 0.001), respectively. The prevalence of left ventricular hypertrophy decreased from 63% to 25%. Left ventricular fractional shortening increased from 34 +/- 2% to 41 +/- 3% (p less than 0.05) and the relation between fractional shortening and end-systolic stress did not change. Over the year of sustained blood pressure reduction, the peak velocity of early filling increased from 57 +/- 3 to 63 +/- 4 cm/s (p = 0.07), peak velocity of late filling did not change and the ratio of late to early peak left ventricular filling velocity significantly decreased (p less than 0.05). Plasma atrial natriuretic peptide levels, markedly elevated at entry, decreased from 70 +/- 15 to 41 +/- 8 pg/ml at 1 year (p less than 0.05). Plasma renin activity and catecholamine levels were not altered.(ABSTRACT TRUNCATED AT 250 WORDS)
Phillips
R A
RA
Department of Medicine, Mount Sinai Medical Center, New York, New York 10029.
Ardeljan
M
M
Shimabukuro
S
S
Goldman
M E
ME
Garbowit
D L
DL
Eison
H B
HB
Krakoff
L R
LR
D009320:Atrial Natriuretic Factor / Q000097:blood*; D006332:Cardiomegaly / Q000000981:diagnostic imaging / Q000517:prevention & control*; D002752:Chlorthalidone / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004452:Echocardiography; D004837:Epinephrine / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D009638:Norepinephrine / Q000097:blood*; D012083:Renin / Q000097:blood*; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects
D003692:Delayed-Action Preparations; D009320:Atrial Natriuretic Factor; D012083:Renin; D009543:Nifedipine; D002752:Chlorthalidone; D009638:Norepinephrine; D004837:Epinephrine